Showing 2678 results for "amyotrophic lateral sclerosis (ALS)"

AB Science Will Continue Phase 3 Study Of Masitinib For ALS

AB Science SA, a pharmaceutical company focused on research, advancement and commercialization of protein kinase inhibitors (PKIs) announced that the external Data and Safety Monitoring Board (DSMB) recommended the company’s phase 3 study of masitinib in amyotrophic lateral sclerosis (ALS) be continued. The decision was supported by the drug’s latest safety reports. The current…

ALS Study Shows Benefits of NurOwn Stem Cell Therapy

New York and Israel-based, BrainStorm Cell Therapeutics, Inc., announced positive final results from a clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS). The study reached its main goal, showing that NurOwnâ„¢ is safe and well-tolerated. In addition, the majority of the 14 participants in this study had an improvement (slowing)…

Biogen Idec and Columbia Partner For ALS Genetics Research

A $30 million alliance between Biogen Idec and Columbia University Medical Center was formed to conduct research in genetics and to understand the underlying causes of several diseases such as amyotrophic lateral sclerosis (ALS). This new partnership may help identify new treatment approaches to address the largely unmet clinical needs…

SciFluor Granted U.S. Patent for KCNQ2/3 Activator to Treat ALS and Epilepsy

The U.S. Patent and Trademark Office (USPTO) recently granted clinical stage biopharmaceutical company and subsidiary of Allied Minds, SciFluor Life Sciences, LLC, a patent for one of their novel pipeline compounds, SF0034, a potent and selective neuronal potassium channel activator that is being studied for the treatment of epilepsy, amyotrophic lateral sclerosis…

BrainStorm Cell Therapeutics To Hold Conference Call On Final Results Of Phase 2a Trial Of NurOwnâ„¢ In ALS

BrainStorm Cell Therapeutics Inc. will be holding a conference call and webcast session to discuss data regarding the company’s phase 2a clinical trial of NurOwnâ„¢ for amyotrophic lateral sclerosis (ALS). BrainStorm is a leading biotechnology company in the ALS space that is developing adult stem cell technologies to address neurodegenerative…

New Biotech Company Yumanity Launched to Treat Protein Misfolding Diseases, Like ALS

Yumanity Therapeutics, a new biotechnology company working on the development of drug discoveries for the treatment of conditions caused by protein misfolding, was launched last Monday by well-known leader in the biotech industry Tony Coles, M.D., who is not only the founding investor of the company, but will also serve as its chairman and chief…